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http:WHAT THIS PAPER ADDS
Patients with lower-extremity peripheral artery disease (PAD) have a high risk of mortality but a disparate
outcome according to the clinical severity of the disease. Risk stratiﬁcation of patients with cardiovascular
diseases is important to improve the management and quality of care. There are few risk algorithms for patients
with PAD, often limited to patients with intermittent claudication. At present, no prognostic risk score is
available for the most serious stage of the disease requiring hospitalisation. This is the ﬁrst prognostic risk score
for risk stratiﬁcation in patients hospitalised for PAD, useful for an optimised management.Objectives: This study aims to determine a hospital discharge prognostic risk score for patients with lower-
extremity peripheral artery disease (PAD) with and without revascularisation.
Design, materials and methods: A prognostic score on mortality or non-fatal cardiovascular events was
determined using the database of a multicentre prospective study enrolling consecutive patients hospitalised for
PAD (COhorte de Patients ARTeriopathes, COPART).
Results: We analysed the data of 640 patients in the derivation cohort and 517 in the validation cohort. The risk
score (and corresponding points) included the following factors: age 75e84 years (þ2), 85 years (þ3); previous
myocardial infarction (þ1); creatinine clearance: 30 ml min1 1.73 m2 (þ1.5), 0.30e0.59 (þ1), ankleebrachial
index: <0.3 (þ2), 0.3e0.49 (þ1.5) and >1.3 (þ2); C-reactive protein (CRP) 70 mg l1 (þ2); and association of
statins, anti-platelet agents and renineangiotensin system inhibitors (1.5). The frequency of the composite
outcome increased signiﬁcantly with the predicted risk: low risk (0 point), 2%; medium (0.5e2 points), 12.8%;
high (2.5e4 points), 23%; very high (4.5 points): 42.2%. The model had a good performance in terms of
discrimination (C-statistic 0.74 and 0.76) and calibration (HosmereLemeshow 0.65).
Conclusions: We propose the validated COPART risk score for hospitalised severe PAD. This prognostic risk score
is based on six variables easily identiﬁable in clinical practice. Our study highlights the favourable prognostic
impact of the prescription at discharge of combined drug therapies.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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//dx.doi.org/10.1016/j.ejvs.2013.01.034Patients with lower-extremity peripheral artery disease
(PAD) are known to be at high risk of mortality but with
disparate outcomes depending on the clinical severity. The
estimated death rate of a patient with intermittent claudi-
cation is 15% after 5 years, whereas in patients with
ischaemic rest pain, this risk is 25% after 1 year.1 Risk scores
are used in cardiology for stratiﬁcation of patients. As an
illustration, in case of acute coronary syndrome, the indi-
cation for speciﬁc treatment depends on the level of the
N. Pros et al. 489patient’s risk score.2 There is a lack of consensus on the
usefulness of risk scores in secondary prevention. However,
the existence of short-, intermediate- and long-term risk
scores enables to individuate and quantify the role of
different, sometimes unattended, risk factors and may
improve management and quality of care. There are few risk
algorithms for patients with PAD.3e5 At present, no prog-
nostic risk score is available for unselected hospitalised
patients in the most serious stage of the disease requiring
hospitalisation, that is, patients with severe claudication
and those with ischaemic rest pain, independently the type
of treatment.
The main aim of this study was to develop and validate
a 1-year hospital discharge prognostic risk score, using the
data of a multicentre registry.
MATERIALS AND METHODS
The COhorte de Patients ARTeriopathes (COPART) is a multi-
centre registry prospectively collecting exhaustive data about
all patients consecutively hospitalised for PAD. The patients
included in the COPARTregistry have been recruited from the
same type of hospitals (university hospitals), but from three
different kinds of department: department of internal
medicine in Bordeaux, of vascular surgery in Limoges and of
vascular medicine in Toulouse. In each centre, patient care
was provided according to the usual practice, without any
change in management strategy. The methodology of the
COPART registry has already been published elsewhere.6Inclusion criteria
To be included, each patient required the following criteria:
age >18 years, consent to participate in the study and
referred to the hospital speciﬁcally for clinical PAD of
atherosclerotic origin. The clinical presentations included
either an intermittent claudication (IC), associated with an
abnormal ankleebrachial index (ABI) <0.90 or >1.30 or, in
the case of normal ABI at rest, a positive treadmill test
(Strandness protocol) and/or an arterial stenosis >50%
revealed by duplex ultrasound and/or angiography, or
ischaemic rest pain, or ulceration and gangrene or acute
lower-limb ischaemia related to a documented PAD with
signiﬁcant arterial stenosis. Cases with acute ischaemia
following bypass surgery or endovascular procedures were
also included.Exclusion criteria
Patients for whom follow-up was improbable, those with
arterial occlusive disease not related to atherosclerosis (iliac
endoﬁbrosis, inﬂammatory arterial disease, Buerger’s
disease, entrapment syndromes, etc.), those with acute
ischaemia without lower-limb atherosclerosis (embolic) and
those refusing to participate were excluded from the study.Data collection
Data were prospectively and consecutively collected from
patients hospitalised for PAD. The nurses of the studyreviewed all the patients hospitalised in the departments
every day and proposed inclusion for those with inclusion
criteria and without exclusion criteria.
Furthermore, the lists of all the patients hospitalised with
a diagnosis-related group (DRG) corresponding to PAD were
regularly compared to the list of patients included in the
registry.
A computerised case-record form was ﬁlled in for each
patient. The initial characteristics along with clinical and
therapeutic data on admission, during hospitalisation and at
discharge were collected. Similarly, clinical events occurring
during hospitalisation and within the ﬁrst year of follow-up
were collected.The data collected at admission included: age,
gender, cardiovascular disease (CVD) risk factors and PAD
clinical presentation using the Rutherford classiﬁcation. The
CVD risk factors were deﬁned as follows: diabetes was
deﬁned by documented medical history, the use of oral anti-
diabetic agents or insulin or fasting plasma glucose levels
1.26 g l1; dyslipidaemia was deﬁned by a documented
medical history, use of lipid-lowering agents for this purpose
or fasting low-density lipoprotein (LDL)-cholesterol
100 mg dl1; hypertension was deﬁned by documented
medical history and use of antihypertensive drugs for this
purpose, or systolic blood pressure (SBP) 140 mmHg or
diastolic blood pressure (DBP) 90 mmHg at admission
determined by the average of the ﬁrst two measurements.
Patients were considered as current smokers if they were
smoking at least one cigarette per day. Patients were
considered past-smokers if they had stopped smoking at least
1 month prior to inclusion in the study. The following CVDs
were noted, according to documented medical history:
angina pectoris or myocardial infarction (MI), heart failure,
atrial ﬁbrillation, presence of a pacemaker at admission,
cerebrovascular disease (CBVD) including ischaemic or hae-
morrhagic stroke as well as transient ischaemic attack.
Chronic kidney disease was deﬁned by previous history or
noted according to the estimated glomerular ﬁltration rate
(eGFR) according to the Modiﬁcation of Diet in Renal Disease
(MDRD) Study equation, and chronic kidney disease was
deﬁned when eGFR was <60 ml min1 1.73 m2.
To collect all events occurring after hospital discharge the
sequential procedure consisted in contacting the patients
themselves, mailing to the general practitioner (and/or
cardiologists/angiologists) and, ﬁnally, consulting mortality
data at the registrar’s ofﬁce. In the case of hospitalisation,
a physician from the research group analysed hospital-
discharge letters.
Outcome deﬁnition
The main outcomes were the occurrence of all-cause
mortality or non-fatal stroke or non-fatal MI at 1 year.
Development of the prognostic risk score
Two groups were determined: one with patients hospital-
ised in the Toulouse centre (derivation cohort), used for the
conception of the risk score, and one with patients hospi-
talised in Bordeaux and Limoges centres (validation cohort)
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STATA software (STATA 7.0, Stata Corporation College
Station, TX, USA). In the univariate analyses, factors asso-
ciated with the occurrence of the composite outcome in the
ﬁrst year of follow-up were researched in the derivation
cohort; differences were tested using the chi-squared or
Fisher’s exact test (in the case of few numbers) for cate-
gorical data, or using Student’s or ManneWhitney tests (in
the case of skewed distribution) for continuous data.
Still in the derivation cohort, a backward stepwise logistic
regression (including all variables related to the occurrenceTable 1. Baseline characteristics of the derivation and validation coho
Characteristics Derivation cohort (n ¼
Age >65 years 425 (66.4)
Age (years mean  SD) 70.2  13
Men 438 (68.4)
Rutherford grades:
Intermittent claudication 179 (28)
Ischaemic rest pain 52 (8.1)
Ulceration or gangrene 345 (53.9)
Acute limb ischaemia 64 (10)
Previous history
Myocardial infarction 135 (21)
Cerebrovascular disease (stroke, TIA) 93 (14.5)
Heart failure 68 (10.6)
Atrial ﬁbrillation 114 (17.8)
Chronic kidney disease 107 (16.6)
Cardiovascular risks factors
Hypertension 448 (70)
Hypercholesterolaemia 336 (52.8)
Current smokers 165/636 (25.9)
Diabetes mellitus 272/587 (42.2)
ABI
1.3 71/587 (12.1)
0.9e1.29 21/587 (3.6)
0.7e0.89 66/587 (11.2)
0.5e0.69 148/587 (25.2)
0.3e0.49 144/587 (24.5)
<0.3 137/587 (23.3)
PAD level
Suprapopliteal 231/581 (39.8)
Infrapopliteal 350/581 (60.2)
eGFR ml/min1 1.73 m2
>60 332/639 (52)
31e60 230/639 (36)
30 77/639 (12)
CRP us 70 UI 141 (18.6)
Treatment during the hospital stay
Angioplasty 258 (40.3)
Bypass surgery 50 (7.8)
Angioplasty or bypass 306 (47.8)
Amputation 88 (13.7)
Drug therapies at discharge
Antiplatelet agents (APA) 554 (86.6)
b-Blockers 179 (28)
ACE inhibitors or ARBs 424 (66.2)
Statins 499 (77.9)
APA and statins and RAS inhibitors 222 (34.6)
Abbreviations: ABI: ankle-brachial index, APA: antiplatelet agents, ACE
angiotensin-receptor blockers, RAS: renineangoitensin system inhibitor
reactive protein; TIA: transient ischaemic attack.of the outcome at a threshold p < 0.20 in the univariate
analysis) was used to identify factors independently asso-
ciated with the outcome occurrence. Only factors remaining
independently associated with the outcome occurrence
with a 5% signiﬁcance level (p < 0.05) were retained in the
ﬁnal model.
For each variable or variable’s modality remaining in the
ﬁnal model, the beta coefﬁcient was used to allocate
a number of points. The sum of these points for each
patient provided the individual risk score. For easier reading
and memorisation, a simpliﬁed score was calculated byrts.
640) n (%) Validation cohort (n ¼ 517) n (%) p Value
338 (65.3) 0.766
70.5  12 0.766
395 (76.4) 0.003
128 (24.8) 0.0001
65 (12.6)
274 (53)
50 (9.6)
99 (19.2) 0.413
77 (14.9) 0.863
59 (11.4) 0.587
109 (21.5) 0.117
71 (13.7) 0.018
367 (71.3) 0.64
298 (57.9) 0.07
114/505 (22.6) 0.19
262/321 (47.9) 0.03
55/321 (17.1) 0.0001
31/321 (9.7)
51/321 (15.8)
87/321 (27.1)
66/321 (20.6)
31/321 (9.7)
97/360 (26.5) 0.0001
263/360 (73.5)
354/500 (70.8) 0.0001
101/500 (20.2)
45/500 (9)
79 (38.7) 0.0001
84 (16.3) 0.0001
78 (15) 0.0001
158 (30.6) 0.0001
110 (21.3) 0.001
367 (71.5) 0.0001
129 (25.1) 0.222
263 (50.8) 0.0001
306 (59.6) 0.0001
98 (19.1) 0.0001
: inhibitors angiotensin-converting enzyme inhibitors, ARBs:
s; ref: reference; eGFR: estimated glomerular ﬁltration rate; CRP: C-
Table 2. Univariate analysis of patients’ characteristics and all-cause
mortality or non-fatal cardiovascular events in the derivation
cohort.
Characteristics Hazard ratio p Value age
N. Pros et al. 491dividing by 5 the number of points allocated to each vari-
able or variable’s modality in the ﬁnal model. Quartiles of
the score were used to deﬁne four classes of risk: low risk,
medium risk, high risk and very high risk.(IC 95%) adjusted
Age <55 yrs ref
Age 55e64 yrs 1.8 (0.68e4.57) 0.24
Age 65e74 yrs 1.6 (0.64e4.04) 0.308
Age 75e84 yrs 4.9 (2.14e11.3) 0.0001
Age 85 yrs 9.3 (3.82e22.9) 0.0001
Women 0.78 (0.49e1.22) 0.283
Rutherford grades
Intermittent
claudication
ref
Ischaemic rest pain 5.4 (2.03e14.5) 0.0001
Ulceration or
gangrene
4.05 (1.86e8.83) 0.0001
Acute limb
ischaemia
5.1 (2.02e8.84) 0.0001
Previous history
Myocardial
infarction
1.79 (1.10e2.90) 0.017
Cerebrovascular
disease (stroke AIT)
1.18 (0.68e2.05) 0.540
Heart failure 2.53 (1.45e4.43) 0.001
Cardiovascular risks factors
Hypertension 0.55 (0.35e0.83) 0.182
Hypercholesterolaemia 0.69 (0.45e1.06) 0.003
Current smokers 0.95 (0.52e1.73) 0.872
Diabetes mellitus 1.39 (0.92e2.10) 0.016
ABI:
1.3 3.25 (1.62e6.51) 0.001
0.5e1.29 ref
0.3e0.49 2.06 (1.12e3.79) 0.02
<0.3 2.61 (1.43e4.76) 0.002
PAD level infrapopliteal
versus suprapopliteal
1.28 (0.77e2.13) 0.343
eGFR ml/min1 1.73 m2
>60 ref
31e60 2.08 (0.95e2.43) 0.082
30 3.02 (1.65e5.54) 0.001
CRP us 70 UI
versus <6.4 UI
2.59 (1.34e4.98) 0.004
Treatment during the hospital stay
Angioplasty 0.68 (0.43e1.05) 0.085
Bypass surgery 1.07 (0.49e2.35) 0.848
Angioplasty
or bypass
0.73 (0.48e1.11) 0.144
Amputation 1.18 (0.67e2.05) 0.560
Drug therapies at discharge
Antiplatelet
agents (APA)
0.51 (0.30e0.87) 0.001
b-Blockers 1.48 (0.93e2.35) 0.561
ACE inhibitors or ARBs 0.71 (0.53e1.23) 0.332
Statins 0.59 (0.37e0.94) 0.001
APA and statins
and RAS inhibitors
0.58 (0.31e0.81) 0.001
Abbreviations: ABI: ankle-brachial index, APA: antiplatelet agents,
ACE: inhibitors angiotensin-converting enzyme inhibitors, ARBs:
angiotensin-receptor blockers, RAS: renineangoitensin system
inhibitors; ref: reference; eGFR: estimated glomerular ﬁltration
rate; CRP: C-reactive protein.Validation of the score
We obtained observed survival curves and rates of the
occurrence of the composite ‘end’ point according to the
four classes of risk (quartile of the score) both in the deri-
vation and in the validation cohort. The discriminant value
of the score was assessed in both cohorts using receiver
operating characteristics (ROC) curves, area under the curve
(AUC) calculations and the C statistic. The ﬁnal model ob-
tained in the derivation cohort was applied to the validation
cohort, and the HosmereLemeshow test was used to
compare observed and predicted rates of occurrence of the
composite ‘end’ point and to validate the performance of
the model in terms of calibration.
RESULTS
Over the study period, from 17 May 2004 to 7 July 2009,
1531 patients were included, out of whom 111 patients
were excluded because of deviation from the protocol (the
same patient was included twice and some patients lacked
an objectively conﬁrmed PAD), 34 were lost to follow-up,
165 did not reach the 1-year anniversary date of follow-up
and 64 died during hospitalisation. Finally, 1157 patients
were taken into account for the analysis: 640 came from the
Toulouse centre (derivation cohort) and 517 came from the
Bordeaux and Limoges centres (validation cohort). In the
derivation cohort, the median age was 71.6 years (inter-
quartile range, 60.7e80.6 years) and 68.4% were men. In
the validation cohort, the median age was 72.5 years
(interquartile range, 61.1e79.9 years) and 76.4% were men.
The characteristics of the two cohorts are described in
Table 1. The two cohorts were comparable in terms of age,
prevalence of prior vascular events, hypertension, hyper-
cholesterolaemia and smoking habits. In both cohorts we
observed high rates of ulcers or gangrene and a majority of
patients had an ABI <0.5. However, differences between
the two cohorts were observed for diabetes, Rutherford
grades, revascularisation drug therapies at discharge,
previous history of heart failure, atrial ﬁbrillation and
chronic renal disease. In the derivation cohort, <50% of
patients underwent revascularisation, with a predominance
of angioplasty, while in the validation cohort, revascular-
isation was performed in 30% of patients. After 1 year, the
composite ‘end’ point all-cause mortality and non-fatal
cardiovascular events had occurred in 123 (19.2%) and 105
(20.3%) of the participants in the derivation and validation
cohorts, respectively (p ¼ 0.12). Almost all events were
fatal (death 94.3%, n ¼ 116; non-fatal MI 3.3%, n ¼ 4; non-
fatal stroke 2.4%, n ¼ 3). In the derivation and the valida-
tion cohorts cardiovascular deaths represented, respec-
tively, 51.7% and 48% of all-cause mortality (p ¼ 0.23).
Table 2 displays the results from the univariate analysis
conducted in the derivation cohort to identify variables
Figure 1. Rates of the composite outcome according to the score
risk quartile in both cohorts.
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were included in the initial model. After multivariate anal-
ysis, only six factors were found to be independent risk
factors: age, prior history of MI, C-reactive protein (CRP)
levels, ABI, eGFR and treatment combining statins, Ras
inhibitors and APA. These factors were retained for the
development of the prognostic risk score (Table 3). In the
derivation cohort, the median score was 2 points
(minimum, 1.5; maximum, 9.5). In the validation cohort, the
median score was 2 points.
The derivation cohort was divided into four risk score
groups (quartiles): Low risk: 0 point, Medium risk: 0.5e2
points, High risk: 2.5e4 points, Very high risk: 4.5 points.
The composite outcome rates at 1 year were respectively
2%, 12.8%, 23% and 42.2% (p < 0.0001). The same signiﬁ-
cant risk stratiﬁcation was observed in the validation cohort
(Fig. 1). The score risk correctly stratiﬁed the subgroups in
both populations (Figs. 2 and 3). In both populations, the
model had a good performance in terms of discrimination
(C-statistic 0.76 for the derivation cohort and 0.74 for the
validation cohort) (Fig. 4). We observed also a good
performance of the model in terms of calibration: no
signiﬁcant differences were found between observed and
calculated composite end-point rates in the validation
cohort (HosmereLemeshow test: p ¼ 0.65) (Fig. 5). These
good performances were obtained both in the subgroup of
patients treated by angioplasty or bypass during the
hospital stay (C-statistic 0.75 for the derivation cohort and
0.72 for the validation cohort; HosmereLemeshow test:
p ¼ 0.67) and in the subgroup without any revascularisation
(C-statistic 0.78 for the derivation cohort and 0.76 for the
validation cohort; HosmereLemeshow test: p ¼ 0.62).DISCUSSION
Our study conﬁrmed the very poor prognosis of patients
hospitalised for PAD, although this group of patients is very
heterogeneous, with 1-year risk of all-cause mortality and
non-fatal MI or stroke ranging from 2% to 40%, according to
the patients’ characteristics.
To our knowledge, this is the ﬁrst study to propose a risk
score with external validation through a new series of
patients with or without revascularisation. The score had
a very good predictive value in spite of the differences
between the derivation and validation cohorts, in terms ofTable 3. Derivation cohort: multivariate analysis and prognostic risk sc
Characteristics Odds ratio IC 95%
Age 75e84 yrs 3.09 (1.28e7.47)
Age 85 yrs 4.69 (1.8e12.2)
History of myocardial infarction 1.73 (1.03e2.9)
CRP 70 UI 2.35 (1.17e4.7)
ABI <0.3 2.54 (1.36e4.76)
ABI 0.3e0.49 1.97 (1.04e3.72)
ABI 1.3 2.65 (1.26e5.58)
eGFR >30e60 ml/min1 1.73 m2 1.68 (1.03e2.74)
eGFR 30 ml/min1 1.73 m2 2.29 (1.21e4.31)
APA and statins and RAS inhibitors 0.46 (0.29e0.73)
Bold indicates the most signiﬁcant values.severity of patients and management: this conﬁrms the
very good performance of the score and its exportability.Prognostic factors
As expected, an age 75 years was independently predic-
tive of all-cause mortality or non-fatal cardiovascular events
after 1 year.3,7 Similarly, elevated CRP levels were found
associated with increased risk of events. Ridker et al.8 re-
ported high level of CRP in patients developing PAD. In
another report,9 CRP was found associated with the
progression of PAD over time. In patients with severe PAD,
high sensitive CRP was already reported as strongly
predictive of fatal and non-fatal cardiovascular
outcomes.10,11 Unsurprisingly, history of MI was found
independently associated with increased risk of all-cause
mortality or non-fatal CVD outcomes. According to the
REduction of Atherothrombosis for Continued Health
(REACH) registry,12 the risk of events after 1 year was higher
in patients with atherothrombosis at several sites. Steg
et al.12 found 21.6% of major cardiovascular events at 1
year in patients with two or three different sites of vascular
damage compared with 12.5% in patients with single-site
involvement. In patients with a prior history of both coro-
nary heart disease and PAD, the rate of a major event at 1
year was 23.1% and was 17.4% in patients with PAD. In
a series of 1560 patients with critical limb ischaemia, Ber-
telé et al.13 found history of MI as being predictive ofore. HosmereLemeshow test (p ¼ 0.75).
p Value b Points
0.01 1.13 D2
0.002 1.54 D3
0.004 0.55 D1
0.02 0.85 D2
0.003 0.68 D2
0.04 0.93 D1.5
0.01 0.97 D2
0.04 0.52 D1
0.01 0.82 D1.5
0.001 0.73 L1.5
Figure 2. In the derivation cohort KaplaneMeier’s event-free survival curves according to the score risk quartiles.
N. Pros et al. 493mortality and CVD non-fatal events at 1 year, with a relative
risk of 1.84, very similar to our results. In contrast to
a Dutch study,3 we did not ﬁnd any signiﬁcant association
between cardiovascular risk factors and outcome. This
difference may be explained by the fact that our population
study included a majority of patients with advanced PADFigure 3. In the validation cohort KaplaneMeier’s event-frewith high rates of severe co-morbidities such as renal
failure, as well as high CRP level. In addition, histories of MI,
as well as altered ABI (in particular ABIs above 1.3), are
conditions that already integrate cardiovascular risk factors.
In line with other reports, we found that decreased ABI was
a marker of poor prognosis, with a reversed proportionale survival curves according to the score risk quartiles.
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Figure 4. In both cohorts ROC curves of prognostic risk score.
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48,294 patients conﬁrmed that high ABI was predictive of
cardiovascular and all-cause mortality.
Renal failure is a risk factor of cardiovascular morbidity
and mortality.19 Decreased renal function is known to be
associated with increased risk of mortality in patients with
advanced PAD, independently of risk factors such as dia-
betes and hypertension.20e22Treatments
Several speciﬁc therapeutic trials have shown the beneﬁts
of anti-platelet agents (APAs), statins and angiotensin-con-
verting enzyme inhibitors (ACE-Is) on vascular morbidity
and mortality in patients with PAD.23e27 Currently, the
recommended medication therapy for PAD comprises three
types of long-term treatments: APAs, statins and ACE-Is.1 A
combination of these three types of treatment was asso-
ciated in our study with a favourable prognosis.
Concerning revascularisation, this treatment tended to
add a protective effect (odds ratio (OR) 0.8, conﬁdence
interval (CI) 0.5e1.25) without reaching statistical signiﬁ-
cance (p ¼ 0.316). After medical and surgical discussion,Figure 5. In the validation cohort comparison predicted versus obse
endpoint, HosmereLemeshow test (p ¼ 0.65).around 50% of patients were treated only medically. Some
of them already had revascularisation procedures and had
no further possibility of revascularisation; for others the
ratio between the risk and the beneﬁt of revascularisation
was considered too low (i.e., poor general condition and
severe sepsis). The study was not targeted to evaluate the
impact of revascularisation on mortality. Therefore, we did
not calculate the number of subjects needed to show
a signiﬁcant difference between mortality in patients with
and without revascularisation. We cannot exclude that in
a larger or different cohort this difference would be statis-
tically signiﬁcant.The risk score
To stratify PAD patients’ risk, two kinds of ‘end’ points were
possible: mortality or amputation and/or death .In the
literature, the ﬁrst is considered to be more suitable for
a long- or middle-term risk score.3 A score of amputation
and/or death appears more pertinent for short-term prog-
nosis (intra-hospital or 30 days).4,5 For our score we chose
all-mortality as primary ‘end’ point. Our risk score is the ﬁrst
published score with external validation focussed on hos-
pitalised patients with PAD treated or not treated with
angioplasty or bypass. Two other scores were published:
one4 to stratify the immediate postoperative outcome of
patients undergoing infrainguinal surgical revascularisation
for critical lower-limb ischaemia (CLI) and the second5 to
predict amputation-free survival in the CLI population
treated with bypass. Our risk score is relatively comparable
to the one published in outpatients by Feringa et al.3 since
ﬁve out of our six variables are common. However, our
study included a more contemporary series of patients,
with high rates of prescription of the recommended ther-
apies in the setting of secondary prevention. In addition to
the validation of our risk score, we were interested in its
exportability: the calibration was satisfying, with no signif-
icant differences found between observed and calculated
outcome rates in the validation cohort and in the subgroupsrved endpoint rates according to deciles of predicted composite
N. Pros et al. 495of patients with or without revascularisation. This risk score
had a good discriminant value with a C-statistic comparable
to what was observed for the score established by Feringa
et al.3 Thus, with a limited number of variables easily ob-
tained by interview and biological assessment, the patient’s
mid-term risk may be stratiﬁed, which may optimise his
management.
LIMITATIONS
Even if selection bias was limited because very few patients
were lost during follow-up, some limitations should be
considered in our study.
First, it should be noted that our score was established
with patients hospitalised in tertiary-care teaching hospi-
tals, with a signiﬁcant proportion of severe cases, and did
not apply to ambulatory outpatients.
Second, the limited number of patients included may
underestimate the impact on the prognosis of the patients
of some variables: these results should be conﬁrmed on
a more extended population.
In conclusion, we propose the validated COPART risk
score for the 1-year risk stratiﬁcation of patients hospital-
ised for severe PAD. This prognostic risk score is based on
hospital-discharge patients’ characteristics and includes six
variables easily identiﬁable in clinical practice. In addition,
our study highlights the favourable prognostic impact on
the observance of the recommendations for drug therapies
for the secondary prevention of patients with PAD.
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